I am a passive income investor. I make my money work for me and get more money to invest. This way, I can supplement my ...

Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson ...

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

A 49-study meta-analysis showed that the mean number of discontinuation symptoms 1 week after stopping an antidepressant was ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Owning dividend stocks is an easy way to build wealth. There are hundreds of companies that pay dividends regularly and by ...

Optum Rx officials said they now have eliminated reauthorization requirements for more than 140 chronic disease medications.

What is Schizophrenia?Schizophrenia is a chronic and often debilitating mental disorder, is characterized by symptoms such as ...

Caplyta may cause serious side effects, but these are not common. The following list may not include all possible serious side effects of the drug. For more information, you can refer to Caplyta ...